Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association

Christensen, Sarah Friis; Scherber, Robyn M.; Brochmann, Nana; Goros, Martin; Gelfond, Jonathan; Andersen, Christen Lykkegaard; Flachs, Esben Meulengracht; Mesa, Ruben A.

doi:10.3390/cancers12082202

Cited by 14 publications

(11 citation statements)

References 114 publications

(159 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who were younger, had a higher BMI, used aromatase inhibitors, and had a history of chemotherapy were more likely to experience sexual symptoms. Our findings may be partially confirmed by the fact that BMI was associated with symptom burden, and breast cancer patients with a history of chemotherapy had long-term hypoactive sexual desire disorder 32,33 . This finding will provide evidence to detect or predict breast cancer patients with a higher risk of sexual symptoms and will also be helpful in developing and implementing tailored management for this subgroup.…”

Section: Discussionsupporting

confidence: 69%

“…Our findings may be partially confirmed by the fact that BMI was associated with symptom burden, and breast cancer patients with a history of chemotherapy had long-term hypoactive sexual desire disorder. 32,33 This finding will provide evidence to detect or predict breast cancer patients with a higher risk of sexual symptoms and will also be helpful in developing and implementing tailored management for this subgroup. A study showed that vaginal moisturizers, sexual education, and group-based psychosocial intervention may be helpful in improving sexual symptoms among patients undergoing endocrine therapy.…”

Section: E302mentioning

confidence: 90%

See 1 more Smart Citation

Symptom Profiles and Related Factors Among Breast Cancer Patients Undergoing Endocrine Therapy

et al. 2022

View full text Add to dashboard Cite

Background: To provide person-centered symptom management, the interindividual variability in breast cancer patients merits further exploration. However, how sociodemographic and clinical characteristics influence symptom profile membership in endocrine therapy for breast cancer is still unknown. Objectives: This study aimed to explore symptom profiles of breast cancer patients undergoing endocrine therapy and to identify sociodemographic and clinical characteristics among symptom subgroup members. Methods: A cross-sectional study was conducted, and participants were invited to complete a general information questionnaire and Functional Assessment of Cancer Therapy-Endocrine Subscale. Latent profile analysis, univariate analysis, and multinomial logistic regression were performed to explore symptom profiles and identify interindividual variability. Results: Three distinct subgroups were identified: "all high" (9.8%), "all moderate but high sexual symptoms" (25.4%), and "all low" (64.8%). Age, body mass index, main payment source for medical expenses, type of endocrine therapy, and history of breast cancer treatment were factors that determined membership in these 3 symptom subgroups. Conclusion: Patients' demographic and clinical characteristics were associated with their endocrine therapy-related symptom profiles. In general, those younger in age who pay out of pocket for medical expenses, use aromatase inhibitors, present a history of chemotherapy, and have a higher body mass index have a greater risk of symptom burden. Implication for Practice: The findings of this study will

show abstract

Section: Discussionsupporting

confidence: 69%

Section: E302mentioning

confidence: 90%

Symptom Profiles and Related Factors Among Breast Cancer Patients Undergoing Endocrine Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Obesity is known to incite a chronic inflammatory state with increased circulating cytokines [16]. A combined analysis of two large survey studies demonstrated that obesity among patients with MPNs correlated with increased overall symptom burden as well as an increased level of nearly all individual symptoms assessed [17]. Notably, being underweight was also associated with an increased symptom burden compared to those with normal BMI.…”

Section: Figurementioning

confidence: 99%

Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions

Yoon

Pettit

2021

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction: Myelofibrosis (MF) is a complex and aggressive hematologic malignancy resulting from JAK/STAT-driven myeloproliferation and abnormal fibrogenesis. The clinical manifestations are heterogeneous and negatively impact quality of life and survival. JAK inhibitors improve symptoms and splenomegaly to a variable degree in a proportion of patients, but the effects for many patients are insufficient or short-lived.Areas covered: This review examines the constellation of symptoms that befall patients with MF, describes methods to quantify and serially monitor these symptoms, and evaluates pharmacologic and non-pharmacologic interventions for disease-related symptoms. The review also includes a discussion of areas of unmet medical need, and proposes future methods for meeting this need. Expert opinion: The treatment landscape for MF is evolving rapidly. The most effective therapies or combinations of therapies will likely simultaneously impact both the malignant hematopoietic stem cell and mechanisms of aberrant fibrogenesis that drive this disease. The goals of treatment for patients with myelofibrosis should be to improve length and quality of life. Clinical trials must be designed with these goals in mind, with endpoints focused on overall survival and symptom reduction, as opposed to surrogate endpoints such as spleen volume reduction.

show abstract

“…Second, a published article presents the prevalence and severity of anxiety and depression and the association of anxiety and depression with different factors in ET, PV, MF, and MPN-U participants from the MPNhealthSurvey [32]. Third, a published article presents the association between body mass index (BMI) and total symptom burden and symptom severity by BMI in ET, PV, MF, and MPN-U participants from the MPNhealthSurvey and the international Fatigue Study combined [33].…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark

Brochmann

Flachs

Christensen

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Previous studies have clarified that many patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) have burdensome symptom profiles and accordingly impaired functioning and quality of life (QoL). In Denmark, all MPN patients are affiliated with public hospitals and because of a healthcare system financed by taxpayers these patients do not have any financial costs related to the hematological disease. Diagnoses are recorded for all patients in hospitals, and diagnosis codes are communicated to the National Patient Register (NPR). Owing to this, it was possible to contribute to the elucidation of Philadelphia-negative MPN patients’ health-related quality of life (HRQoL), by conducting a nationwide, population-based, cross-sectional HRQoL survey of these patients with cost-free access to the best available, suitable medical treatment. The survey contained validated questionnaires covering functioning, symptom burden, symptom profile, QoL, and additional questions on lifestyle. Information on comorbid diagnoses was obtained from the NPR. The participants’ HRQoL was compared to the general population. Moreover, differences in HRQoL across essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN participants were investigated, adjusted for age, sex, comorbidity, and lifestyle. To the best of our knowledge this is the first survey of HRQoL in patients with unclassifiable MPN. A total of 2228 Philadelphia-negative MPN patients participated. The participants reported their HRQoL to be inferior to the general population, but the difference was minor. The differences in HRQoL across groups of participants with different MPN subtypes were subtle. Fatigue and sexual problems were prevalent and burdensome. Overall, participants reported a slightly healthier lifestyle compared to the general population.

show abstract

Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association

Cited by 14 publications

References 114 publications

Symptom Profiles and Related Factors Among Breast Cancer Patients Undergoing Endocrine Therapy

Symptom Profiles and Related Factors Among Breast Cancer Patients Undergoing Endocrine Therapy

Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions

Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark

Contact Info

Product

Resources

About